March 24, 2014
1 min read

Ocriplasmin injection showed high rate of success in select VMT patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

LISBON, Portugal — Real-life data of a selected, homogeneous group of patients with vitreomacular traction only, treated by a single injection of ocriplasmin, showed higher efficacy compared with MIVI-TRUST data.

“We had an overall success rate, in terms of resolution of the traction, in 52% of the patients, compared with the 26% rate of the MIVI-TRUST. Patients with focal traction did even better, with a 61% success rate,” Peter Szurman, MD, said in an industry-sponsored symposium at the Controversies in Ophthalmology meeting.

The study on Jetrea (ocriplasmin, ThromboGenics/Alcon) was conducted in a clinic in Germany and enrolled 23 eyes of 22 patients with VMT. Eighteen eyes had focal adhesion, and five had broad adhesion. The follow-up was 4 weeks.
“Ocriplasmin worked even better than expected in VMT and showed a remarkably higher success rate of 61% vs. 20% in focal vs. broad adhesion,” Szurman said.

A significant decrease in macular thickness and increase in vision were also obtained. Eyes with focal traction again had the best results, with a mean gain of more than two lines.

“Improvement was up to four lines in some cases. There were eyes that lost one line but will be re-evaluated in the long term,” Szurman said.

In his opinion, although not all cases are successful, ocriplasmin should be offered to patients as an alternative to wait-and-see.

“It is true that traction might resolve spontaneously, but patients are, in the meantime, disturbed by image distortion, which affects performance at work and life quality,” he said.

Disclosure: Szurman received a speaker’s fee from Alcon.